Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Mendelian randomization study of obesity and type 2 diabetes in hospitalized COVID-19 patients

Hui-Qi Qu a, Jingchun Qu a, Joseph Glessner a,b,c, Hakon Hakonarson a,b,c,d,e,⁎

a The Center for Applied Genomics, Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA
b Department of Pediatrics, The Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
c Division of Human Genetics, Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA
d Division of Pulmonary Medicine, Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA
e Faculty of Medicine, University of Iceland, Reykjavik, Iceland

ARTICLE INFO

Article history:
Received 5 November 2021
Accepted 24 January 2022

Keywords:
COVID-19
Hospitalization
Mendelian randomization
Obesity
Type 2 diabetes

ABSTRACT

Background: Both obesity and type 2 diabetes (T2D) are reported to be highly enriched in hospitalized COVID-19 patients. Due to the close correlation between obesity and T2D, it is important to examine whether obesity and T2D are independently related to COVID-19 hospitalization.

Objective: To examine the causal effect of obesity and T2D in hospitalized COVID-19 patients using Mendelian randomization (MR).

Research design and methods: This two-sample MR analysis applied genetic markers of obesity identified in the genome wide association study (GWAS) by the GIANT Consortium as instrumental variables (IVs) of obesity; and genetic markers of T2D identified by the DIAGRAM Consortium as IVs of T2D. The MR analysis was performed in hospitalized COVID-19 patient by the COVID-19 Host Genetics Initiative using the MR-Base platform.

Results: All 3 classes of obesity (Class 1/2/3) were shown as the causal risk factors of COVID-19 hospitalization; Obesity, but not T2D, is a primary risk factor of COVID-19 hospitalization.

Conclusions: Obesity, but not T2D, is a primary risk factor of COVID-19 hospitalization.

© 2022 Elsevier Inc. All rights reserved.

1. Introduction

The pandemic of Coronavirus Disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection [1]. SARS-CoV-2 is not as virulent as SARS, and a large number of patients are asymptomatic or suffer only mild symptoms [2]. A large number of infected patients (~80%) have been asymptomatic or with mild symptoms [3], which has made the viral spread more difficult to control. On the other hand, a number of risk factors increased the severity and the rate of COVID-19-associated hospitalization, including obesity and type 2 diabetes (T2D) [4–7]. To investigate the risk factors of COVID-19-associated hospitalization is warranted for the development of effective preventive therapeutic approaches. In particular, obesity, especially patients with a body mass index (BMI) of ≥35 kg/m², has been shown as a strong and independent determinant of severe COVID-19 in large studies as reviewed by Stefan et al. [8].

Recently, genome wide association studies (GWAS) on severe COVID-19 have yielded important information on the disease pathogenesis [9–11]. The COVID-19 Host Genetics Initiative is a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the COVID-19 pandemic [11]. The summary statistics data are publicly available (https://www.covid19hg.org). Our recent analysis on the COVID-19 Host Genetics Initiative results demonstrated genetic correlations between COVID-19 and obesity as well as T2D [12]. However, it is hard to tell whether the correlations between COVID-19 and obesity/T2D are direct or indirect. Obesity contributes to metabolic syndrome [13], and increases the risk of T2D. Bearing in mind the close connection between obesity and T2D, it is important to examine whether the two reported risk factors are independently related to COVID-19 hospitalization.

Mendelian randomization (MR) uses genetic variants as proxies to simulate randomized clinical trial of risk factors and to determine causal effects [14], based on the results of well-designed genetic studies on each disease, e.g., large sample genome wide association studies (GWAS). By the two sample MR approach using the MR-Base platform [15], this study aims to investigate the causal effects of obesity and T2D in COVID-19-associated hospitalization in European populations based on two large GWASs on obesity and T2D, including the GWAS on obesity harboring 263,407 individuals of European ancestry [16], and the European T2D GWAS meta-analysis constituting 12,171 cases and 56,862 controls [17].

https://doi.org/10.1016/j.metabol.2022.155156
0026-0495/© 2022 Elsevier Inc. All rights reserved.
2. Research design and methods

2.1. Data sources

This is a two-sample MR study designed to assess whether obesity or T2D was causally related to the risk of COVID-19-associated hospitalization. Single nucleotide polymorphisms (SNP) that were systematically identified by large sample GWASs served as the IVs to represent the exposures, i.e., obesity or T2D.

IVs for obesity: The SNPs associated with obesity were identified by the large scale GWAS on obesity in European populations by the Genetic Investigation of ANthropometric Traits (GIANT) Consortium [16]. The obesity phenotype was further divided into 3 clinical classes [18], e.g., class 1 obesity (30 ≤ BMI < 35, kg/m²) including 55,229 cases and 104,894 controls; class 2 obesity (35 ≤ BMI < 40) including 15,334 cases and 97,858 controls; class 3 obesity (BMI ≥ 40) including 3986 cases and 67,010 controls. The GIANT meta-analysis included multiple cohorts, while some cohorts had no class 2 and/or class 3 cases. The controls for the 3 classes of obesity were subjects with BMI < 25.

IVs for T2D: The SNPs associated with T2D were identified by the large sample European T2D GWAS meta-analysis [17], including 12,171 cases and 56,862 controls of European ancestry from the DIAGRAM Consortium [19].

The outcome measure was COVID-19-associated hospitalization based on the study of the COVID-19 Host Genetics Initiative Release 4 on 6406 cases and 902,088 controls of European ancestry (Dataset ID GCST010779, Released on October 20, 2020, https://www.covid19hg.org/results/r4/) [11], contained in the MR-Base platform (https://www.mrbase.org/) [15]. Consequently, the MR results were re-examined in the most recent data release by the COVID-19 Host Genetics Initiative, COVID19-hg GWAS meta-analyses round 6 (Released on June 15, 2021, https://www.covid19hg.org/results/r6/), including 24,274 hospitalized cases and 2,061,529 controls from different human populations [20]. In addition, we further assessed the causal effects of obesity and T2D in critically ill cases of COVID-19, i.e., individuals requiring respiratory support in hospital or deceased due to the disease, including 8779 cases and 1,001,875 controls [20].

All the above GWAS studies have been performed in adult populations.

2.2. SNP selection

SNPs for obesity: autosomal SNPs were selected by P value < 1E−05 from the obesity association analysis, in addition to being informative in the association test with COVID-19 hospitalization. Based on these results, 1361 SNPs were associated with class1 obesity; 1133 SNPs were associated with class 2 obesity; and 252 SNPs were associated with class 3 obesity (Supplementary Table 1). After the clumping procedure to obtain independent significant using MR-Base [15] (Supplementary Table 2),

SNPs for obesity: autosomal SNPs were selected by P value < 1E−05 from the obesity association analysis, in addition to being informative in the association test with COVID-19 hospitalization. Based on these results, 1361 SNPs were associated with class1 obesity; 1133 SNPs were associated with class 2 obesity; and 252 SNPs were associated with class 3 obesity (Supplementary Table 1). After the clumping procedure to obtain independent significant using MR-Base [15] (Supplementary Table 2),

(1) 52 SNPs were left as the IVs for class 1 obesity: 25 SNPs were also associated with class 2/3 obesity, or were in linkage disequilibrium (LD) r² > 0.277 with an IV SNP for class 2/3 obesity; and 27 SNPs were specifically associated with class 1 obesity.

(2) 41 SNPs were left as the IVs for class 2 obesity: 3 SNPs were also associated with both class 1 and 3 obesity; 20 additional SNPs were also associated with class 1 obesity, or in LD with a class 1 SNP; 3 additional SNPs were also associated with class 3 obesity, or in LD with a class 3 SNP. 15 SNPs were specifically associated with class 2 obesity.

(3) 15 SNPs were left as the IVs for class 3 obesity: 7 SNPs were also associated with class 1/2 obesity, or in LD with class 1/2 SNPs; and 8 SNPs were specifically associated with class 3 obesity.

SNPs for T2D: 637 autosomal SNPs had P value < 1E−05 from the T2D association analysis, and were informative in the association test of COVID-19 hospitalization (Supplementary Table 3). After the clumping procedure to obtain independent significance using MR-Base [15], 55 SNPs were left as IVs for T2D (Supplementary Table 4). Among these IVs, 3 SNPs were also associated with obesity, i.e., rs4506565 in LD with the obesity SNP rs10885402 with r² = 0.515; rs9936385 in LD with the obesity SNP rs9923233 with r² = 1.000; and rs9947403 in LD with the obesity SNP rs8084515 with r² = 0.968. The biological explanation of the pleiotropy of these 3 IVs is that they may increase the risk of T2D by causing obesity. SNPs for T2D: 637 autosomal SNPs had P value < 1E−05 from the T2D association analysis, and were informative in the association test of COVID-19 hospitalization (Supplementary Table 3). After the clumping procedure to obtain independent significance using MR-Base [15], 55 SNPs were left as IVs for T2D (Supplementary Table 4). Among these IVs, 3 SNPs were also associated with obesity, i.e., rs4506565 in LD with the obesity SNP rs10885402 with r² = 0.515; rs9936385 in LD with the obesity SNP rs9923233 with r² = 1.000; and rs9947403 in LD with the obesity SNP rs8084515 with r² = 0.968. The biological explanation of the pleiotropy of these 3 IVs is that they may increase the risk of T2D by causing obesity.

2.3. Statistical analysis

The MR analysis was done using the MR-Base platform [15]. The conventional random effects inverse variance weighted (IVW) analysis was used for the MR analysis. Heterogeneity of the causal estimates across all SNPs was tested by Q statistics. The effect of each SNP is presented in a forest plot. MR Egger analysis is also shown in the forest plots, which suffers from low statistical power. The effect of each single instrument on the overall effect was shown in the plot of the leave-one-out analysis.

3. Results

The MR analysis acquired significant P values for all the 3 classes of obesity, suggesting each class of obesity as a causal risk factor of COVID-19 hospitalization (Table 1). No significant heterogeneity was seen across different SNPs. The leave-one-out analysis showed that no single instrument had significant impact on the overall effect (Supplementary Figs. 1–3). The causal effect of each SNP is represented in the forest plots (Supplementary Figs. 4–6). The MR analysis on T2D and COVID-19 hospitalization was not significant with a negative β value. The leave-one-out analysis and forest plots are shown in Supplementary Figs. 7–8. Considering the potential bias by the 3 pleiotropic IVs also associated with obesity, we re-performed the MR analysis with the rest of the 52 SNPs, and repeated the non-significance with a negative β value (Table 1).

To confirm the above results, we retested the above sets of obesity and T2D IVs in the most recent data release by the COVID-19 Host
Genetics Initiative, COVID-19-hg GWAS meta-analyses round 6 [20]. As shown by the MR re-analysis (Table 1), more significant P values were acquired for all the 3 classes of obesity, while non-significance was repeated for T2D. These results suggest that T2D itself is not a causal risk factor of COVID-19 hospitalization. In addition, we further assessed the causal effects of obesity and T2D in critically ill cases of COVID-19, including $\text{8779 cases and 1,001,875 controls}$ [20]. As the results, we acquired statistical significance in both the IVs for class 1 obesity and those for class 3 obesity. A trend of association is seen in the IVs for class 2 obesity, but lack of statistical significance. Instead, no association was seen with type 2 diabetes (Table 2).

4. Discussion

Obesity has been reported as a risk factor of COVID-19 severity by previous studies [4,7,21,22], Obesity is a common health problem, affecting about 315 million people world-wide [23]. Obesity may cause metabolic syndrome [13], and increases the risk of a number of chronic diseases, including but not limited to T2D and hypertension, both have been reported as risk factors of severe COVID-19 in clinical studies [4,24]. However, T2D is closely related to obesity-induced insulin resistance. It is therefore difficult to differentiate any independent effects of T2D in COVID-19 hospitalization, without the confounding effect of obesity by an epidemiological approach. The MR analysis using obesity or T2D specific genetic markers as the instrumental variables is a robust approach to address this issue.

In the recent publication by the COVID-19 Host Genetics Initiative [20], BMI, but not T2D, has been identified with association with increased risk of COVID-19 severity. With genetic effect estimates of BMI from the UK Biobank, Leong et al. have also shown that higher BMI is a causal risk factor for COVID-19 susceptibility and severity [25]. With these interesting findings, some important topics warrant further investigation. In the previous two studies [20,25], the single nucleotide polymorphisms (SNPs) associated with BMI and T2D were mainly identified in the European populations, while the COVID-19-associated SNPs were identified in multi-ethnic samples. For the causal effect of BMI, which class of obesity is it from, i.e., from only severe obesity, or from all classes of obesity? Obesity-associated SNPs may also be associated with T2D. Does these SNPs bias the MR results of T2D? In both the previous reports [20,25], BMI/T2D-associated SNPs with genome-wide significance (i.e., P ≤ 5E−08) were used as the instrumental variables (IVs). According to our study, the overall genetic risk of a complex disease/trait may be better captured at the cutoff of P-value ≤ 1E−05, while stricter cutoff may cause the missing of informative SNPs, and looser may introduce noise by including SNPs with spurious association [26]. Could the null effect of T2D be due to missing genetic information?

In our analysis, all 3 classes of obesity were shown to be causal risk factors of COVID-19 hospitalization with positive and significant β values, although the effect size of the association with COVID-19 hospitalization is not comparable across different classes of obesity due to the application of different sets of IVs. In further, we repeated the statistical significances of the IVs for class 1 obesity and those for class 3 obesity in critically ill cases of COVID-19, despite the smaller sample size and the decreased statistical power. Our study implies that obesity itself is the primary risk factor of COVID-19 hospitalization, independent of complications caused by more severe classes of obesity. As reviewed by Popkin et al. [21], obesity is associated with severe form of the 2009 H1N1 influenza [27], the 2012 Middle East respiratory syndrome coronavirus (MERS-CoV) infection [28], and severe COVID-19. In addition to risk of severe COVID-19 caused by obesity-related chronic metabolic diseases, hormone and nutrient dysregulation, respiratory dysfunctions, and immune/inflammatory dysfunctions in obesity, may all contribute to the risk of severe COVID-19 [21]. This viewpoint is supported by our MR analysis results, showing all 3 tiers of obesity correlated with COVID-19 hospitalization. As a limitation of the current study, the role of metabolically healthy obesity (MHO) in COVID-19 remains to be investigated. Individuals with MHO have metabolically healthy fat distribution, e.g. increased gluteofemoral and leg fat mass [29], If MHO could be demonstrated of no association with severe COVID-19, precise prevention of severe COVID-19 could be practiced towards cases with metabolically unhealthy obesity, rather than a particular class of obesity.

 Interestingly, our MR analysis showed that T2D doesn’t increase the risk of COVID-19 hospitalization as an independent factor. Clinically observed risk of T2D in severe COVID-19 might be due to underlying obesity. However, compared with obesity, T2D tends to develop on the basis of long term obesity and insulin resistance, and is therefore associated with aging [30]. Individuals with genetic susceptibility of T2D may develop T2D disease as they age. Due to this reason, the risk effect of T2D in COVID-19 hospitalization may be underestimated by the MR approach. With this possibility, however, previous studies observed no evidence of increased hospitalization rate for COVID-19 in type 1 diabetes (T1D) children [31,32]. These observations may suggest diabetes itself is not a significant risk factor of COVID-19 hospitalization.

In conclusion, this MR analysis showed that obesity, but not T2D, is the risk factor of COVID-19 hospitalization. While obesity is a risk factor of severe COVID-19, information supported by the previous clinical studies, the null effect of diabetes is also supported by the lack of association between T1D and COVID-19 hospitalization. The outcome data of this study, the COVID-19 Host Genetics Initiative Release 4, was released on October 20, 2020. In contrast, the first approval of the use of any COVID-19 vaccine was by the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) with a temporary regulatory approval on 2 December 2020 [https://www.gov.uk/government/publications/regulatory-approval-of-pfizer-biontech-vaccine-for-covid-19/conditions-of-authorisation-for-pfizerbiontech-covid-19-vaccine]. Therefore, the null effect of diabetes observed in this study was not biased by prioritized vaccination in T2D patients. It is worth to

---

| Table 1 | The MR analysis on obesity and type 2 diabetes in COVID-19 hospitalization. |
|---------|--------------------------------------------------|
| Inverse variance weighted | N of SNP | $\beta$ | Se | P value | Q statistics | Qdf | Q_pval |
| European populations (6406 cases and 902,088 controls) | Class 1 obesity | 52 | 0.105 | 0.041 | 0.0114 | 58.47 | 51 | 0.220 |
| | Class 2 obesity | 41 | 0.085 | 0.032 | 0.0086 | 46.26 | 40 | 0.230 |
| | Class 3 obesity | 15 | 0.078 | 0.029 | 0.0062 | 12.59 | 14 | 0.559 |
| | Type 2 diabetes | 55 | 0.012 | 0.027 | 0.0527 | 48.14 | 54 | 0.699 |
| | Type 2 diabetes minus 2 obesity SNPs | 52 | 0.008 | 0.030 | 0.7854 | 46.37 | 51 | 0.658 |
| Different human populations (24,274 cases and 2,061,529 controls) | Class 1 obesity | 42 | 0.106 | 0.023 | 3.30E−06 | 47.21 | 41 | 0.234 |
| | Class 2 obesity | 35 | 0.066 | 0.020 | 8.48E−04 | 55.59 | 34 | 0.011 |
| | Class 3 obesity | 14 | 0.054 | 0.015 | 2.33E−04 | 12.16 | 13 | 0.514 |
| | Type 2 diabetes | 48 | −0.025 | 0.017 | 0.1441 | 43.92 | 47 | 0.601 |
| | Type 2 diabetes minus 2 obesity SNPs | 45 | −0.030 | 0.020 | 0.1288 | 43.24 | 44 | 0.504 |

Abbreviations: se, standard error of ($\beta$); df, degrees of freedom.

---

| Table 2 | The MR analysis on obesity and type 2 diabetes in critically ill cases of COVID-19.* |
|---------|--------------------------------------------------|
| Inverse variance weighted | N of SNP | $\beta$ | Se | P value | Q statistics | Qdf | Q_pval |
| Class 1 obesity | 42 | 0.113 | 0.037 | 0.0024 | 37.77 | 41 | 0.615 |
| Class 2 obesity | 35 | 0.055 | 0.030 | 0.0623 | 38.83 | 34 | 0.261 |
| Class 3 obesity | 14 | 0.060 | 0.025 | 0.0170 | 7.41 | 13 | 0.880 |
| Type 2 diabetes | 48 | −0.018 | 0.025 | 0.4831 | 35.18 | 47 | 0.898 |
| Type 2 diabetes minus 2 obesity SNPs | 45 | −0.024 | 0.028 | 0.4001 | 34.01 | 44 | 0.861 |

* The COVID-19 Host Genetics Initiative, COVID-19-hg GWAS meta-analyses round 6, including 8779 cases and 1,001,875 controls.
emphasize that the null association between T2D and COVID-19 hospitalization needs to be explained with caution, considering limitations of the current MR approach. Previous retrospective observational studies have shown that T2D is associated with hospitalization and severe COVID-19 [33,34]. T2D is characterized by low-grade inflammation [35]. Poorly glycemic control and long diabetes duration could contribute to severe COVID-19. The T2D CWAS data may predict the risk of T2D, but contain no information about glycemic control and diabetes duration in the patients. These factors as the potential risk of severe COVID-19 couldn’t be excluded by the null effect of T2D in this MR study, and warrant for large scale epidemiological study. In addition, both T2D and T1D have long term complications that are clinically reported of association for greater COVID-19 severity. Diabetes Care. 2020;43:e72–e4.

[6] Stefan N, Birkenfeld AL, Schulze MB. Global pandemics interconnected – obesity, impaired metabolic health and COVID-19. Nat Rev Endocrinol. 2021;17:135–49.

[7] Group SC-G. Genomewide association study of severe COVID-19 with respiratory failure. N Engl J Med. 2020;383:1522–34.

[8] Paire-Castineira E, Cluizel S, Klcko L, Bretherick AD, Rawlik K, Passio D, et al. Genetic mechanisms of critical illness in Covid-19. Nature. 2021;591:92–8.

[9] Initiative C-HG. The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic. Eur J Hum Genet. 2020;28:715.

[10] Chang X, Li Y, Nguyen K, Qu H, Liu Y, Glessner J, et al. Genetic correlations between COVID-19 and a variety of traits and diseases. The Innovation. 2021;2:100112.

[11] Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab. 2004;89:2595–600.

[12] Emdin CA, Khera AV, Kathiresan S. Mendelian randomization. Jama. 2017;318:1925–6.

[13] Hemani G, Zheng J, Elsworthy B, Wade KH, Huberland Y, Baird D, et al. The MR-Base platform supports systematic causal inference across the human phenotype. elife. 2018;7:e34408.

[14] Berndt SI, Gustafsson S, Mååg R, Ganna A, Wheeler E, Feitoja MF, et al. MR-Base-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture. Nat Genet. 2013;45:501–12.

[15] Mahajan A, Go MJ, Zhang W, Below JF, Gaulton KJ, Ferreira T, et al. Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. Nat Genet. 2014;46:234–44.

[16] Organization WH. Obesity: preventing and managing the global epidemic; 2000.

[17] Morris AP, Vought BF, Teslovich TM, Ferreira T, Segre AV, Steinthorssdottir V, et al. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet. 2012;44:581.

[18] COVID-19 Host Genetics Initiative. Mapping the human genetic architecture of COVID-19. Nature. 2021;600:472–7.

[19] Popkin BM, Du S, Green WD, Beck MA, Algaidh T, Herbst CH, et al. Individuals with obesity and COVID-19: a global perspective on the epidemiology and biological relationships. Obes Rev. 2020;21:e13128.

[20] Badawi A, Ryoo SG. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV); a systematic review and meta-analysis. Int J Infect Dis. 2016;49:1293–33.

[21] Stefan N. Causes, consequences, and treatment of metabolically unhealthy fat distribution. Lancet Diabetes Endocrinol. 2021.4;100112.

[22] Gao F, Zheng KI, Wang X-B, Sun Q-F, Pan K-H, Wang T-Y, et al. Obesity is a risk factor for greater COVID-19 severity. Diabetes Care. 2020;43:e72–e4.

[23] Lai C-C, Shih T-P, Ko W-C, Tang H-J, Hsueh P-R. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemiology, transmission and clinical syndrome. JAMA. 2020;323:1406–42.

[24] Schiffrin EL, Flack JM, Boyd JB, Brenner LN, Meigs JB, Florez JC, Mercader JM. Cardiometabolic risk factors for COVID-19-associated hospitalization: COVID-19-associated hospitalization survival analysis. JAMA. 2020;323:2870–7.

[25] Leong A, Cole JB, Brenner LN, Meigs JB, Florez JC, Mercader JM. Cardiometabolic risk factors for severe COVID-19 and a variety of traits and diseases. The Innovation. 2021;2:100112.

[26] Wang X-B, Sun Q-F, Pan K-H, Li Y, Glessner J, et al. Impaired metabolic health and COVID-19. Elife. 2020;9:e56352.

[27] Morris AP, Vought BF, Teslovich TM, Ferreira T, Segre AV, Steinthorssdottir V, et al. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet. 2012;44:581.

[28] Badawi A, Ryoo SG. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV); a systematic review and meta-analysis. Int J Infect Dis. 2016;49:1293–33.

[29] Stefan N. Causes, consequences, and treatment of metabolically unhealthy fat distribution. Lancet Diabetes Endocrinol. 2021.4;100112.

[30] Gong Z, Muzumdar RH. Pancreatic function, type 2 diabetes, and metabolism in aging. J Intern Med. 2012;2012.

[31] Vangsostenhoven R, Martens P-J, van Eels F, Mooyen C, Noahels V, Van Crombrugge P, et al. Risks of severe COVID-19 and mortality in patients with diabetes: a systematic review of case reports. Diabetes Care. 2020;43:2870–7.

[32] Haverkamp-Beyaert J, Rees K, Perring JC, Kerneis SA, Morris EM, Goyder C, et al. Risks of and from SARS-CoV-2 infection and COVID-19 in people with diabetes: a systematic review of reviews. Diabetes Care. 2021;44:2790–811.

[33] Raddone I, Schiaffini R, Cherubini V, Maffess C, Scaramuzza A. Has COVID-19 delayed the diagnosis and worsened the presentation of type 1 diabetes in children? Diabetes Care. 2020;43:2870–7.

[34] Harbans-Boyce J, Rees K, Perring JC, Kerneis SA, Morris EM, Goyder C, et al. Risks of and from SARS-CoV-2 infection and COVID-19 in people with diabetes: a systematic review of reviews. Diabetes Care. 2021;44:2790–811.

[35] Carlsbad A, Byou SG. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV); a systematic review and meta-analysis. Int J Infect Dis. 2016;49:1293–33.